by Josh Friedman
An artificial intelligence-driven algorithm used a novel liquid biopsy assay to differentiate women with ovarian … Read more
By Heidi Splete
Many women with cancer want advice for managing sexual function issues, and clinicians are tuning in, new studies suggest.
Decreased sexual function is a side effect of many types of cancer, notably uterine, cervical, ovarian, and breast … Read more
Clearity’s Perspective: At the SGO meeting several presentations described how circulating tumor DNA (ctDNA) may be a new, personalized, sensitive tool to help evaluate treatment de-escalation, monitor minimal residual disease (MRD), and track treatment response in ovarian cancer. The application … Read more
Clearity’s Perspective: Previous research in different types of cancer has suggested that there is a relationship between a cancer patient’s gut microbiota (microorganisms that live in the digestive tract) composition and the response to immune checkpoint inhibitor therapy; however,
… Read moreBy Mike Basset
Risk management strategies including bilateral salpingo-oophorectomy (BSO) for ovarian cancer and MRI surveillance for breast cancer were associated with a significant reduction in mortality for women with BRCA1/2 sequence variations, according to results from two cohort studies … Read more
By Fay Lin, PhD
A major bottleneck in early detection is the molecular heterogeneity between ovarian cancer (OC) patients, which limits the likelihood of identifying individual biomarkers that are shared among patients. In a new study “A personalized probabilistic … Read more
By Ashling Wahner
Although the antibody-drug conjugate (ADC) mirvetuximab soravtansine-gynx (Elahere) is associated with a high rate of ocular toxicity in patients with folate receptor α (FRα)-positive, platinum-resistant ovarian cancer, the real-world incidence of this adverse effect (AE) in this … Read more
Clearity offers emotional support to people diagnosed with ovarian cancer and their caregivers through our Steps Through OC program. If you would like personalized, one-to-one assistance with navigating the impact of an ovarian cancer diagnosis, our team of OC Counselors … Read more
By Erin T. Welsh, MA
Asian, Black and Hispanic women with … Read more
By Andrea Anderson
NEW YORK – An Italian team led by investigators at Humanitas University has come up with a test for detecting early-stage high-grade serous ovarian cancer (HGSOC) that relies on DNA sequencing of cervical smear samples collected during … Read more
Research has shown mindful meditation can reduce stress, relieve pain.
Clearity offers psychosocial support to caregivers through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with caring for a loved one with an ovarian cancer diagnosis, our team of OC … Read more
By Rylan DeStefano
An artificial intelligence model called IRON (Integrated Radiogenomics for Ovarian Neoadjuvant therapy) shows an 80% accuracy rate in the prediction of therapy outcomes for patients with ovarian cancer. The artificial intelligence model focuses specifically on the volumetric … Read more
Clearity’s Perspective: A phase I clinical trial studying the antibody-drug conjugate (ADC) raludotatug deruxtecan (DS-6000a, R-DXd) shows early encouraging activity in heavily pretreated ovarian cancer. The antibody portion of raludotatug deruxtecan targets CDH6 (found in about 65-85% of ovarian cancers) … Read more
By Mary Caffrey
Delayed diagnoses. Symptoms that are dismissed or misinterpreted. Feelings of anxiety because no one can offer a clear explanation for their condition.
These are just some of the experiences of women who have low-grade serous ovarian cancer … Read more
More than 95% of BRCA1 or BRCA1 pathogenic variants would have been missed by DTC testing, largest such study showed
By Mark Fuerst
Direct-to-consumer (DTC) genetic testing has limited use as a screening tool for identifying individuals at risk of hereditary breast or ovarian cancer, especially in those of non-Ashkenazi Jewish descent, researchers reported.
Most current DTC genetic tests evaluate … Read more
Clearity’s Perspective: The combination of avutometinib and defactinib has shown encouraging activity in Low-Grade Serous Ovarian Cancer. Updated results from the RAMP 201 trial suggest that the combination is active regardless of the number of prior therapies patients have received. … Read more
By Hayden E. Klein
Patients with ovarian cancer saw a 70% improvement in overall survival (OS) 3 years after undergoing a multidisciplinary surgical approach compared with previous approaches to therapy, according to a study published in Annals of Surgical Oncology… Read more
Oncologists treating ovarian cancer need to be proactive to prevent or reduce the likelihood of adverse effects associated with poly (ADP-ribose) polymerase (PARP) inhibitors, noted authors of a review in the ASCO Educational Book.
William Tew, MD, of Memorial Sloan … Read more
Key Points:
